{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"021-517-319-699-954","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"021-517-319-699-954","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11722,"type":"PATENT","title":"University of Cologne - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":488,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8375,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: uni* koeln
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 343
Search Applicants and Owners separately: uni* koeln
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 343
(a) contacting at least one testing molecule with the (poly-)peptide and/or protein being associated with or related to the reproduction of the tuberculosis inducing germ;
(b) detection and/or analysis whether the testing molecule is able to inhibit or at least to reduce the activity of the (poly-)peptide and/or protein being associated with or related to the reproduction of the tuberculosis inducing germ."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["Method of identifying and/or retrieving a pharmacologically active agent being able to inhibit or at least to reduce the expression and/or activity of a (poly-)peptide and/or a protein of a tuberculosis inducing germ, wherein the (poly-)peptide and/or protein is associated with or related to the reproduction, especially cell division, of the tuberculosis inducing germ, the method comprising the steps of:
(a) incorporating at least one testing substance and/or a DNA-sequence encoding for the testing substance and/or its respective RNA-sequence into a germ being associated with tuberculosis and being able to express the (poly-)peptide and/or the protein of the tuberculosis inducing germ, wherein the (poly-)peptide and/or protein is associated with or related to the reproduction, especially all divison, of the tuberculosis germ, the germ being preferably selected from the group of the genus Mycobacterium;
(b) detection and/or analysis whether the testing substance is able to inhibit or at least to reduce the expression and/or activity of the (poly-)peptide and/or protein being associated with or related to the reproduction of the tuberculosis inducing germ."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["Method of improving the pharmacological properties of a pharmacologically active agent identified by one of the methods according to Claim 9 or 10, the method comprising the steps of
(a) identifying and/or locating the binding site of the pharmacologically active agent to the (poly-)peptide and/or protein being associated with or related to the reproduction of the tuberculosis inducing germ and/or identifying and/or locating the binding site of the pharmacologically active agent to the DNA-Sequence, especially to the gene, and/or to the corresponding RNA-Sequence, encoding for the (poly-)peptide and/or protein being associated with or related to the reproduction of the tuberculosis inducing germ;
(b) modifying the binding site of the pharmacologically active agent, especially via molecular modelling; and
(c) modifying the pharmacologically active agent with the proviso that the specificity and/or affinity and/or avidity of the binding site of pharmacologically active agent is optimized and/or increased with respect to the (poly-)peptide and/or protein being associated with or related to the reproduction of the tuberculosis inducing germ and/or with the proviso that the specificity and/or affinity and/or avidity of the binding site of pharmacologically active agent is optimized and/or increased with respect to the DNA-Sequence, especially to the gene, and/or to the corresponding RNA-Sequence."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["Method of modification of a pharmacologically active agent identified or improved by one of the methods according to one of Claims 9 to 11, wherein the pharmacologically active agent is further modified in order to attain
(i) a modified active centre, a modified activity spectrum and/or a modified organ specificity, especially lung specificity, and/or
(ii) improved properties with respect to the incorporation and/or uptake properties with respect to the tuberculosis inducing germ and/or
(iii) an improved activity and/or
(iv) a reduced toxicity (an improved therapeutic index) and/or
(v) reduced side effects and/or
(vi) a reduced toxicity (an improved therapeutic index) and/or
(vii) a retarded onset and/or beginning of the therapeutic activity and/or duration of the therapeutic activity and/or
(viii) modified pharmacological parameters, especially resorption, distribution, cell penetration, metabolism and/or excretion, and/or
(iv) modified physicochemical parameters, especially solubility, hygroscopic properties, colour, flavour, smell, stability, application form, and/or
(x) a modified general specificity, especially organ/tissue-specificity, and/or
(xi) a modified application form and/or application route, especially by"],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["Pharmaceutically active agent, especially for the prophylactic and/or therapeutic (curative) treatment of tuberculosis, especially pulmonary tuberculosis, the pharmacologically active agent being able to inhibit or at least to reduce the expression and/or activity of a (poly-)peptide and/or a protein of a tuberculosis inducing germ, the (poly-)peptide and/or protein being associated with or related to the reproduction, especially cell division, of the tuberculosis inducing germ, wherein the pharmacologically active agent is obtainable by the methods according to Claims 9 to 12."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["Pharmaceutical composition, especially for the prophylactic and/or therapeutic (curative) treatment of tuberculosis, especially pulmonary tuberculosis, the pharmaceutical composition comprising an efficient amount, especially a pharmacological effective amount, of at least one pharmacologically active agent being able to inhibit or at least to reduce the expression and/or activity of a (poly-)peptide and/or a protein of a tuberculosis inducing germ, the (poly-)peptide and/or protein being associated with or related to the reproduction, especially cell division, of the tuberculosis inducing germ, wherein the pharmacologically active agent is obtainable by the methods according to Claims 9 to 12 and/or wherein the pharmacologically active agent is defined in one of the Claims 4 to 6."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["Method of treating a human suffering from tuberculosis, especially pulmonary tuberculosis, the method comprising: administering an efficient amount of at least one pharmacologically active agent being able to inhibit or at least to reduce the expression and/or activity of a (poly-)peptide and/or a protein of a tuberculosis inducing germ, the (poly-)peptide and/or protein being associated with or related to the reproduction, especially cell division, of the tuberculosis inducing germ."],"number":15,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}(a) esterification of carboxyl groups and/or(b) esterification of hydroxyl groups with carbonic acids and/or(c) esterification of hydroxyl groups, especially to phosphates, pyrophosphates, sulfates and/or hemisuccinates and/or(d) formation of pharmaceutical acceptable salts and/or(e) formation of pharmaceutical acceptable complexes and/or(f) synthesis of pharmacological polymers and/or(g) introduction of hydrophilic groups and/or(h) introduction and/or exchanging of isosterical and/or bioisosterical groups and/or(i) synthesis of homologous compounds and/or(j) introduction of branched side chains and/or(k) introduction and/or exchange of substituents in aromatic groups and/or side chains and/or modifying of substituent distribution and/or aubstituent arrangement and/or(l) conversion of alkyl substituents into cyclic analoga and/or(m) derivatization of hydroxyl groups into ketals and/or acetals and/or(n) N-acetylization into amides and/or phenylcarbamates and/or(o) synthesis of Mannich-bases and/or imines and/or(p) conversion of ketones and/or aldehydes into Schiff bases, oximes, acetals, ketals, enolesters, oxazolidines, thiozolidines and combinations thereof.(q) reduction of the molecular size, preferably be deletion and/or exchange of amino acids, however, with the proviso that pharmacologically effective motifs of the pharmacologically active agent are at least essentially not affected.